{
  "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
  "docSlug": "a4fc5169399f8913c54f14d18031629c",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 64,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Slide contains three distinct charts comparing IMX-110 against standard of care in mouse models.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/41",
  "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
  "deckJsonHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917.json",
  "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.75
      },
      "kind": "callout",
      "text": "IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f38840e-ef3f-48fc-a081-957d09271dad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Percent Survival After One Cycle of Treatment At Day 22",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21322289-ff80-40fe-b487-7b03f4c3c8a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Best % Change from Baseline in Size of Tumor",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90aca999-f9a8-4c0f-aa04-5d4474a0fe33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.55,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Median Survival In Genetic (KPC) Pancreatic Cancer Mouse Model",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "940e2027-286e-493b-8f91-db22604610cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.28,
        "y": 0.63
      },
      "kind": "list",
      "text": "IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy. IMX-110 response rate surpassed standard of care doxorubicin's response rate of 0%. January 12, 2022 Press Release.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0eb56f82-3b6a-4c18-a17d-fcf540e79858",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.75,
        "y": 0.35
      },
      "kind": "list",
      "text": "IMX-110 + anti-PD-1 produced 63-day median survival. Historically, 42-days is the median survival produced by a 4-drug combination. 2022 plan to commence combination IMX-110 + BeiGene anti-PD-1. January 25, 2022 Press Release.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fadf1a6-9561-44ac-9bd0-8a83a3b50705",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.28,
        "y": 0.25
      },
      "kind": "list",
      "text": "In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs. One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin. May 20, 2022 Press Release.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8edaadf-54f4-4777-944c-731fceedd426",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "IMX-110 Preclinical Data Provides Translational Rationale & PD-1 Combination Rationale",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58350ab5-2db6-4a1a-a203-52dc2eefdb0e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}